Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia

American Journal of Reproductive Immunology

Volumn 73, Issue 5, 2015, Pages 417-427

  Luley, Lydia ^a   Schumacher, Anne ^a   Mulla, Melissa J ^b   Franke, Dirk ^c   Löttge, Michael ^d   Fill Malfertheiner, Sara ^a   Tchaikovski, Svetlana N ^a   Costa, Serban Dan ^a   Hoppe, Berthold ^e   Abrahams, Vikki M ^b   Zenclussen, Ana C ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Internist   (Germany)

^d Hospital Magdeburg   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apoptosis; Low molecular weight heparin; Pregnancy; Regulatory T cell; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CASPASE 3; ENOXAPARIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; CASP3 PROTEIN, HUMAN; CASP3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL POPULATION; CONTROLLED STUDY; DECIDUA; ENZYME ACTIVITY; FEMALE; FIRST TRIMESTER PREGNANCY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACENTA; PLACENTA WEIGHT; PREGNANT WOMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; THROMBOPHILIA; WILD TYPE; ACTIVATED PROTEIN C RESISTANCE; ADULT; ANIMAL; GENETICS; IMMUNOLOGY; MOUSE; PATHOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ANIMALS; ANTICOAGULANTS; CASPASE 3; DECIDUA; FACTOR V; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MICE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; T-LYMPHOCYTES, REGULATORY;

EID: 84927086769     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12348     Document Type: Article

References (56)

1. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
2. Press RD, Bauer KA, Kujovich JL, Heit JA: Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002; 126:1304-1318.
3. Dahlback B: The protein C anticoagulant system: inherited defects as basis for venous thrombosis. Thromb Res 1995; 77:1-43.
4. Ridker PM, Miletich JP, Hennekens CH, Buring JE: Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277:1305-1307.
5. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
6. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13:516-530.
7. Bertina RM, Broekmans AW, van der Linden IK, Mertens K: Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982; 48:1-5.
8. Comp PC, Nixon RR, Cooper MR, Esmon CT: Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984; 74:2082-2088.
9. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M: High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77:825-828.
10. Mansvelt EP, Laffan M, McVey JH, Tuddenham EG: Analysis of the F8 gene in individuals with high plasma factor VIII: C levels and associated venous thrombosis. Thromb Haemost 1998; 80:561-565.
11. Lockshin MD: Pregnancy and antiphospholipid syndrome. Am J Reprod Immunol 2013; 69:585-587.
12. Abrahams VM: Mechanisms of antiphospholipid antibody-associated pregnancy complications. Thromb Res 2009; 124:521-525.
13. Rodger MA: An update on thrombophilia and placenta mediated pregnancy complications: what should we tell our patients? Thromb Res 2013; 131(Suppl 1):25-27.
14. Lykke JA, Bare LA, Olsen J, Lagier R, Arellano AR, Tong C, Paidas MJ, Langhoff-Roos J: Thrombophilias and adverse pregnancy outcomes: results from the Danish National Birth Cohort. J Thromb Haemost 2012; 10:1320-1325.
15. Rodger MA, Betancourt MT, Clark P, Lindqvist PG, Dizon-Townson D, Said J, Seligsohn U, Carrier M, Salomon O, Greer IA: The association of factor V leiden and prothrombin gene mutation and placenta-mediated pregnancy complications: a systematic review and meta-analysis of prospective cohort studies. PLoS Med 2010; 7:e1000292.
16. Mello G, Parretti E, Fatini C, Riviello C, Gensini F, Marchionni M, Scarselli GF, Gensini GF, Abbate R: Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45:86-91.
17. Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, Kahn SR, Magee LA, Rodger M: Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7:58-64.
18. de Vries JIP, van Pampus MG, Hague WM, Bezemer PD, Joosten JH: Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost 2012; 10:64-72.
19. Gris JC, Chauleur C, Molinari N, Mares P, Fabbro-Peray P, Quere I, Lefrant JY, Haddad B, Dauzat M: Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost 2011; 106:1053-1061.
20. Kupferminc M, Rimon E, Many A, Maslovitz S, Lessing JB, Gamzu R: Low molecular weight heparin versus no treatment in women with previous severe pregnancy complications and placental findings without thrombophilia. Blood Coagul Fibrinolysis 2011; 22:123-126.
21. Martinelli I, Ruggenenti P, Cetin I, Pardi G, Perna A, Vergani P, Acaia B, Facchinetti F, La Sala GB, Bozzo M, Rampello S, Marozio L, Diadei O, Gherardi G, Carminati S, Remuzzi G, Mannucci PM; HAPPY Study Group: Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood 2012; 119: 3269-3275.
22. Qublan H, Amarin Z, Dabbas M, Farraj AE, Beni-Merei Z, Al-Akash H, Bdoor AN, Nawasreh M, Malkawi S, Diab F, Al-Ahmad N, Balawneh M, Abu-Salim A: Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb) 2008; 11:246-253.
23. An J, Waitara MS, Bordas M, Arumugam V, Hoffmann RG, Petrich BG, Sinha U, North PE, Sood R: Heparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model. Blood 2013; 121:2127-2134.
24. Lever R, Page CP: Non-anticoagulant effects of heparin: an overview. Handb Exp Pharmacol 2012; 207:281-305.
25. Oberkersch R, Attorresi AI, Calabrese GC: Low-molecular-weight heparin inhibition in classical complement activation pathway during pregnancy. Thromb Res 2010; 125:e240-e245.
26. Girardi G, Redecha P, Salmon JE: Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10:1222-1226.
27. Hochart H, Jenkins PV, Smith OP, White B: Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br J Haematol 2006; 133:62-67.
28. Young E: The anti-inflammatory effects of heparin and related compounds. Thromb Res 2008; 122:743-752.
29. Schumacher A, Zenclussen AC: Regulatory T cells: regulators of life. Am J Reprod Immunol 2014; 72:158-170.
30. Rodger MA, Carrier M, Le Gal G, Martinelli I, Perna A, Rey E, de Vries JI, Gris JC; Low-Molecular-Weight Heparin for Placenta-Mediated Pregnancy Complications Study Group: Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood 2014; 123:822-828.
31. Teles A, Schumacher A, Kuhnle MC, Linzke N, Thuere C, Reichardt P, Tadokoro CE, Hämmerling GJ, Zenclussen AC: Control of uterine microenvironment by foxp3(+) cells facilitates embryo implantation. Front Immunol 2013; 4:158.
32. Zenclussen AC, Gerlof K, Zenclussen ML, Sollwedel A, Bertoja AZ, Ritter T, Kotsch K, Leber J, Volk HD: Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 2005; 166:811-822.
33. Schumacher A, Wafula PO, Bertoja AZ, Sollwedel A, Thuere C, Wollenberg I, Yagita H, Volk HD, Zenclussen AC: Mechanisms of action of regulatory T cells specific for paternal antigens during pregnancy. Obstet Gynecol 2007; 110:1137-1145.
34. Jasper MJ, Tremellen KP, Robertson SA: Primary unexplained infertility is associated with reduced expression of the T-regulatory cell transcription factor Foxp3 in endometrial tissue. Mol Hum Reprod 2006; 12:301-308.
35. Steinborn A, Schmitt E, Kisielewicz A, Rechenberg S, Seissler N, Mahnke K, Schaier M, Zeier M, Sohn C: Pregnancy-associated diseases are characterized by the composition of the systemic regulatory T cell (Treg) pool with distinct subsets of Tregs. Clin Exp Immunol 2012; 167:84-98.
36. Tilburgs T, Scherjon SA, van der Mast BJ, Haasnoot GW, Versteeg-V D Voort-Maarschalk M, Roelen DL, van Rood JJ, Claas FH: Fetal-maternal HLA-C mismatch is associated with decidual T cell activation and induction of functional T regulatory cells. J Reprod Immunol 2009; 82:148-157.
37. Darrasse-Jeze G, Klatzmann D, Charlotte F, Salomon BL, Cohen JL: CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. Immunol Lett 2006; 102:106-109.
38. Mjosberg J, Berg G, Ernerudh J, Ekerfelt C: CD4+ CD25+ regulatory T cells in human pregnancy: development of a Treg-MLC-ELISPOT suppression assay and indications of paternal specific Tregs. Immunology 2007; 120:456-466.
39. Robertson SA, Prins JR, Sharkey DJ, Moldenhauer LM: Seminal fluid and the generation of regulatory T cells for embryo implantation. Am J Reprod Immunol 2013; 69:315-330.
40. Robertson SA, Guerin LR, Bromfield JJ, Branson KM, Ahlstrom AC, Care AS: Seminal fluid drives expansion of the CD4+CD25+ T regulatory cell pool and induces tolerance to paternal alloantigens in mice. Biol Reprod 2009; 80:1036-1045.
41. Schumacher A, Heinze K, Witte J, Poloski E, Linzke N, Woidacki K, Zenclussen AC: Human chorionic gonadotropin as a central regulator of pregnancy immune tolerance. J Immunol 2013; 190:2650-2658.
42. Winger EE, Reed JL: Low circulating CD4(+) CD25(+) Foxp3(+) T regulatory cell levels predict miscarriage risk in newly pregnant women with a history of failure. Am J Reprod Immunol 2011; 66:320-328.
43. Toldi G, Saito S, Shima T, Halmos A, Veresh Z, Vasarhelyi B: The frequency of peripheral blood CD4+ CD25high FoxP3+ and CD4+ CD25- FoxP3+ regulatory T cells in normal pregnancy and pre-eclampsia. Am J Reprod Immunol 2012; 68:175-180.
44. Sasaki Y, Darmochwal-Kolarz D, Suzuki D, Sakai M, Ito M, Shima T, Shiozaki A, Rolinski J, Saito S: Proportion of peripheral blood and decidual CD4(+) CD25(bright) regulatory T cells in pre-eclampsia. Clin Exp Immunol 2007; 149:139-145.
45. Darmochwal-Kolarz D, Kludka-Sternik M, Tabarkiewicz J, Kolarz B, Rolinski J, Leszczynska-Gorzelak B, Oleszczuk J: The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J Reprod Immunol 2012; 93:75-81.
46. Rowe JH, Ertelt JM, Xin L, Way SS: Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 2012; 490:102-106.
47. Vasavada VA, Praveen MR, Shah SK, Trivedi RH, Vasavada AR: Anti-inflammatory effect of low-molecular-weight heparin in pediatric cataract surgery: a randomized clinical trial. Am J Ophthalmol 2012; 154:252-258.
48. Wang XF, Li AM, Li J, Lin SY, Chen CD, Zhou YL, Chen CL, Liu SD, Chen Y: Low molecular weight heparin relieves experimental colitis in mice by downregulating IL-1beta and inhibiting syndecan-1 shedding in the intestinal mucosa. PLoS ONE 2013; 8:e66397.
49. Fu LS, Tsai JJ, Chen YJ, Lin HK, Tsai MC, Chang MDT: Heparin protects BALB/c mice from mite-induced airway allergic inflammation. Int J Immunopathol Pharmacol 2013; 26:349-359.
50. Luan ZG, Naranpurev M, Ma XC: Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation 2014; 37:924-932.
51. Koller M, Kutscha-Lissberg F, Brom J, Weidinger G, Muhr G: Influence of low molecular weight heparin (certoparin) and unfractionated heparin on the release of cytokines from human leukocytes. Inflammation 2001; 25:331-337.
52. Di Simone N, Di Nicuolo F, Castellani R, Veglia M, Tersigni C, Silano M, Tritarelli A, Scambia G, Marana R: Low-molecular-weight heparins induce decidual heparin-binding epidermal growth factor-like growth factor expression and promote survival of decidual cells undergoing apoptosis. Fertil Steril 2012; 97:169-177.
53. Hao LN, Zhang QZ, Yu TG, Cheng YN, Ji SL: Antagonistic effects of ultra-low-molecular-weight heparin on Abeta25-35-induced apoptosis in cultured rat cortical neurons. Brain Res 2011; 1368:1-10.
54. Kukner A, Tore F, Firat T, Terzi EH, Oner H, Balaban YH, Ozogul C: The preventive effect of low molecular weight heparin on CCL(4)-induced necrosis and apoptosis in rat liver. Ann Hepatol 2010; 9:445-454.
55. Yu YH, Shen LY, Zou H, Wang ZJ, Gong SP: Heparin for patients with growth restricted fetus: a prospective randomized controlled trial. J Matern Fetal Neonatal Med 2010; 23:980-987.
56. Hills FA, Abrahams VM, Gonzalez-Timon B, Francis J, Cloke B, Hinkson L, Rai R, Mor G, Regan L, Sullivan M, Lam EW, Brosens JJ: Heparin prevents programmed cell death in human trophoblast. Mol Hum Reprod 2006; 12:237-243.